CURRICULUM VITAE

 

 

Name:                              Xin Wei Wang, Ph.D.                         Date: April 8, 2008

 

Business Address:          Laboratory of Human Carcinogenesis

NIH, NCI

Building 37, Room 3044A

37 Convent Drive, MSC 4255

Bethesda, MD 20892-4255

Tel: (301) 496-2099

Fax: (301) 496-0497

Email: xw3u@nih.gov

Internet: http://ccr.cancer.gov/staff/staff.asp?profileid=5764

 

Education:

B.S., Shanghai First Medical College                                                   1982

M.S., Chinese Academy of Sciences                                                    1984

Ph.D., New York University                                                                1991

 

Post Graduate Education

Postdoctoral Fellowship in cell biology                                                1991‑1992

Roche Institute of Molecular Biology

Nutley, New Jersey

 

IRTA Fellowship in molecular carcinogenesis                                      1992-1995

National Cancer Institute, National Institute of Health

Bethesda, Maryland

 

Employment History

Research Scientist of Institute of Environmental Medicine                   1986-1987

New York University Medical Center, Tuxedo, New York

 

          Senior Staff Fellow of Laboratory of Human Carcinogenesis              1995-1998

          National Cancer Institute, NIH, Bethesda, Maryland

         

          Investigator and Head of Liver Carcinogenesis Section                        1998-2005

Laboratory of Human Carcinogenesis, NCI, Bethesda, Maryland                

 

Adjunct Associate Professor                                                                2002-2005

University of Maryland Cancer Center, Baltimore, Maryland

 

Adjunct Professor                                                                                          2005-presnet

University of Maryland Cancer Center, Baltimore, Maryland

 

Senior Investigator                                                                               2005-present

Head, Liver Carcinogenesis Section

LHC, CCR, NCI, NIH, Bethesda, Maryland

 

Professional Societies:

American Association for Cancer Research (member)

American Association for the Advancement of Science (member)

CCR-NCI HIV and Cancer Virology Faculty (members): CCR-NCI Cellular, Molecular and Developmental Biology Faculty; CCR-NCI Genetics, Genomics, and Proteomics Faculty; CCR-NCI Gene Expression Faculty; CCR-NCI Bioinformatics, Biostatistics and Computational Biology Faculty; CCR-NCI Molecular Targets Faculty; Gastrointestinal Malignancies Faculty; Metastasis Working Group

          International Society of Gastroenterological Carcinogenesis (Board of Directors)

          Society of Chinese Bioscientists in America (member)

          International Liver Cancer Association (Founding member)

 

Administrative Service

          Institutional Service

                    NIH FARE Judge                                                                       2001, 2002, 2004,

                                                                                                                        2005, 2006

                    Member, NCI-UMD Tissue Resource Review Panel                 2000, 2005

                    Chair, LHC Microarray Interest Group                                       2002-present

                    Member, NIH-NCI HCC Clinical Steering Committee               2005-present

                    CCR-NCI Inflammation and Cancer Initiative Discussion          2005

                    Member, CCR-NCI Strategic Plan: focus group                         2006

Co-chair, the biomarkers and molecular targets subgroup, the Center of Excellence in Integrative Cancer Biology and Genomics (CEICBG), CCR, NCI                2007

 

 

          National Service

                    Organizer, International Workshop on Human

                    Hepatocellular Carcinoma, Bethesda, Maryland                          2002

                    The International Society of Gastroenterological

                    Carcinogenesis (Board of Directors)                                           2003-2005

                    NRC Research Advisor                                                              2005-present

                    Co-organizer, NCI-cosponsored Symposium on liver cancer

                    At the Shanghai-Hong Kong Liver Congress                             March 2006

                    Co-organizer, Keystone Symposia, Beijing, China           2007

                    Peer Review Committee Member, American Cancer Society      2007-present

 

          Editorial board

                    Carcinogenesis                                                                           2002-2005

         

          Grant reviewer

          Cancer Research Campaign                                                       1998-2000

          Cancer Research UK                                                                  2003-present

          Jeffress Memorial Trust                                                              2001

          Italian Association for Cancer Research                                    2003-present

          Research Grants Proposal of Hong Kong                                  2004-present

          NIAID, NIDDK, review panels                                                   2006-

                   ACS Study Section on cancer genetics                                       2007-

 

Editorial services (Add-Hoc Reviewer)                                                1995-present

(Listed major journals from over 30)

          Cancer Cell

          Cancer Research

          Gastroenterology

          Genes & Development

          Immunity

          Journal of Biological Chemistry

          Journal of Clinical Investigation

          Journal of National Cancer Institute

          Hepatology

          Molecular and Cellular Biology

          New England Journal of Medicine

          Oncogene

          Proc. Natl. Acad. Sci. USA

 

Teaching Service

          Preceptor, HHMI-NIH Research Scholars Program:

                    1994-1995   Heidi Yeh, MD (University of Pennsylvania)

                    1995-1996   Michael Gibson, MD (University of Maryland)

                    1996-1997   Nissim Khabie, MD (Mayo clinics)

                    1997-1998   Anne Manicone, MD (University of Washington)

                    2003-2004   Brian Zipser, MD (Brown University)

                    2006-           Giang Nguyen (Albany Medical College)

                    2007-           Fei Dong (Case Western Reserve University School of Medicine)

 

          Guest lecturer, the Topics in Molecular Epidemiology course

                    Georgetown University Medical School                                               2000-2004

 

          Thesis Advisor:

                    1996      Jill Coursen, MS, Hood College

                    2002      Qinghai Ye, MD/PhD, Shanghai Medical University

                    2006      Huliang Jia, MD/PhD, Fudan University

                    2007      Guoling Lin, MD/PhD, Fudan University

                    2008      Jiong Shi, MD/PhD, Fudan University

 

          Thesis Committee:

                    1999      Joo-Yeon Yoo, PhD, University of Maryland

         

Current Lab members:

          Marshonna Forgues, BA (1998-), Lab technician

          Anuradha Budhu, PhD (2002-), Staff Scientist

          Taro Yamashita, MD/PhD (2005-), Postdoctoral fellow

          Zhipeng Yu, BA (2006-), Lab technician

          Junfang Ji, MD/PhD (2006-), Postdoctoral fellow

          Steffi Roessler, PhD (2006-), Postdoctoral fellow

          Guoling Lin, MD (2007-), Visiting fellow

          Fei Dong (2007-), Guest researcher

          Jiong Shi, MD (2008-), Visiting fellow

         

Former Lab members:

Jill D. Coursen, MS (1997-1998), Research Scientist II, Genta Incorporated

Ann Tseng, MD (1998-1999), Assistant professor, Oregon Health & Science University

Chuan-Ging Wu, MD/PhD (1998-2001), Staff Scientist, FDA

Haress Rahim, DDS (1999), Dentist, Dental Arts Center

Lily Wong (1999, 2000)

Michele Abbasi (2000)

Teh-Ia Huo, MD (2000-2001), Professor, Yang Ming University

David M. Salvay, MS (2000), Graduate student, Northwestern University

Jin Woo Kim, PhD (2001-2004), Assistant Professor, Wake Forest University School of Medicine

Jessica Sime, PhD (2001-2002), Northwestern University Medical School

Alice Uy (2000, 2001)

Shabina Siddique, MD (2000, 2001), Resident, Johns Hopkins University

Qinghai Ye, MD/PhD (2002), Professor, Liver Cancer Institute, Shanghai

Lavanya Viswanathan (2002)

Wei Wang, PhD (2003-2005), Staff Scientist, FDA

Vivian Takafuji, PhD (2004-2006)

Mi Jung Lim, PhD (2005-2006), Senior Scientist, Biology Laboratory, South Korea

Nicholas Younes (2005), undergraduate student,

Huliang Jia, MD/PhD (2005-2006), Assistant Professor, Liver Cancer Institute, Shanghai

Mindy Wei (2006), Undergraduate student, University of Maryland

Andy Chen (2006), Undergraduate student

Bhumi Patel (2006, 2007), Premed student,

Louie Zhou (2007), Premed student, University of Pennsylvania

Lei Zhao, MD/PhD (2007-2008), Associate professor, Shandong Provincial Tumor Hospital and Institute of Oncology

 

Grant Support

           Principal Investigator                                                                                      1998-2000

           Mechanism of Human liver carcinogenesis.

           DBS Budget Allocation, NCI, NIH

 

           Principal Investigator                                                                                      2000-present

           Mechanism of Human liver carcinogenesis.

           CCR Budget Allocation, NCI, NIH

 

Additional Competitive Funds:

Principal Investigator                                                                                      2001

SAGE transcript profiles. DBS, NCI, NIH;

Total direct costs awarded: $40,000

 

Principal Investigator                                                                                      2001

Molecular profiling of metastatic hepatocellular carcinoma. DBS, NCI

Total direct costs awarded: $19,500

 

Principal Investigator                                                                                      2001

Program travel. DBS, NCI, NIH

Total direct costs awarded: $15,000

 

Principal Investigator                                                                                      2002

International Workshop. CCR, NCI, NIH,

Total direct costs awarded: $25,000

 

Principal Investigator                                                                                      2002

International Workshop. NIH Office of Rare Diseases

Total direct costs awarded: $20,000

 

Principal Investigator                                                                                      2003

Program travel. CCR, NCI, NIH

Total direct costs awarded: $15,000

 

Principal Investigator                                                                                      2004

Program travel. CCR, NCI, NIH

Total direct costs awarded: $15,000

 

Principal Investigator                                                                                      2005

Gene expression profiling of HCC by microarray

Total direct costs awarded: $60,000

 

Principal Investigator                                                                                      2005

MicroRNA expression profiling of HCC

Total director costs awarded: $90,000

 

Principal Investigator                                                                                      2006

Program travel. CCR, NCI, NIH

Total direct costs awarded: $15,000

 

Principal Investigator                                                                                      2006

Affymetrix HTA analysis of HCC

Total director costs awarded: $50,000 (ODRS support)

 

Principal Investigator                                                                                      2007

Program travel. CCR, NCI, NIH

Total direct costs awarded: $15,000

 

Principal Investigator                                                                                      2007

Acquisition of ABI 7900HT Fast Real-Time PCR System

Total direct costs awarded: $90,000

 

Principal Investigator                                                                                      2008

Co-sponsorship of Sino-US joint symposium in ILC

Total direct costs awarded: $30,000

 

Patents and Inventions

         U.S. Patent No. 5,985,829. Screening assays for compounds that cause apoptosis.

         U.S. Patent No. 6,613,318. Methods for identifying inhibitors of Gadd45.

         U.S. PHS Employee Invention. The Establishment of telomerase-immortalized human liver epithelial cell lines.

         PCT Patent application, 60/370,895 (2002). Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma or identifying therapeutic targets.

         U.S. Patent application (2005). Compositions and Methods for Diagnosis and Treatment of Metastatic Disease.

         U.S. Patent application, 60/732,332 (2005). Method of Screening for hepatocellular carcinoma.

         U.S. Patent application (2006). A novel diagnostic and therapeutic strategy for metastatic hepatocellular carcinoma by targeting a unique region of osteopontin.

         U.S. Patent application (2006). Methods of determining the prognosis of an adenocarcinoma.

         Provisional Patent application, 60/884,052 (2006). Methods of determining the prognosis of hepatocellular carcinoma.

         Provisional Patent application, 60/942,833 (2007). Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells.

 

Honors and Awards

          Shanghai First Medical College Best student awards                            1980-1981

          Committee of Pharmaceutics Sinica Best thesis award                          1984

          American Society of Toxicology Travel award                                     1988

          Society of Toxicology Meritorious research award                     1991

          Roche Institute of Molecular Biology Fellowship                                 1991

          NCI CRTA fellowship                                                                          1992-1995

          NIH Technology Transfer Awards                                                       1998, 2000, 2002, 2003, 2004, 2005, 2006, 2007

          Distinguished lecturer, UMBC Greenebaum Cancer Center                 2005

          Visiting professor, Mount Sinai School of Medicine                            2004

 

Major Invited Speeches or Talks

1.         ÒRole of TGFb1 in cell growth regulationÓ. NCI, Bethesda, MD, May 1992

2.         ÒHBV and liver cancerÓ. Life Sciences Symposium on Human Genetics, Association for Chinese Scientists in America, the Great Washington Chapter, April 1993

3.         ÒFunctional interaction between p53 and TFIIHÓ. INSERM Unit, University of Strasbourg, Strasbourg, France, May 1994

4.         ÒRole of p53 in DNA repair and apoptosisÓ. Department of Cell Biology and Genetics, Medical Genetics Center, Erasmus University, Rotterdam, Netherlands, August 1994

5.         ÒFunctional interaction between p53 and TFIIHÓ. Symposium on DNA Repair and Human Syndrome, NIH Research Festivals, September 1994

6.         ÒFunctional interaction between p53 and TFIIHÓ. DNA repair interest group, NIH, Bethesda, MD, March 1995

7.         ÒFunctional interaction between p53 and TFIIHÓ. Genetic Susceptibility and Molecular Carcinogenesis, AACR, Keystone, January 1996

8.         ÒFunctional interaction between p53 and HBxÓ. 1996 Shanghai International Symposium on Liver Cancer & Hepatitis, Shanghai, China, May 1996

9.         ÒFunctional interaction between p53 and TFIIHÓ. Department of Pathology & Oncology, University of Maryland Cancer Center, Baltimore, MD, May 1996

10.      ÒFunctional interaction between p53 and TFIIHÓ. IASLC Workshop, Nancy, France, July 1996

11.      Òp53 and TFIIHÓ. Symposium on apoptosis, Scanning Microscopy International, Chicago, IL, May 1997

12.      ÒRole of Gadd45 in G2/M cell cycle checkpoint controlÓ. Cancer genetics and tumor suppressor genes conference, Frederick, MD, July 1997

13.      Òp53 and genomic instabilityÓ. National Cancer Institute, Bethesda, MD, September 1997

14.      Òp53, DNA helicases and genomic instabilityÓ. XVIII International Congress of Genetics, Beijing, China, August 1998

15.      Òp53, DNA helicases and genomic instabilityÓ. The 5th International Symposium on Dendritic Cells in Fundamental Clinical Immunology, Pittsburgh, PA, November 1998

16.      Òp53, DNA helicases and genomic instabilityÓ. The National Capital Area Branch of the Society for In Vitro Biology, Beltsville, MD, December 1998

17.      ÒNuclear-cytoplasm trafficking and oncogenesisÓ. The 14th Aspen Cancer Conference, Aspen, CO, July 1999

18.      Òp53 and Bloom syndromeÓ. Symposium on DNA Repair and Apoptosis, NIH Research Festivals, Bethesda, MD, September 1999

19.      ÒRole of Gadd45 in G2/M cell cycle checkpoint controlÓ. Department of Biochemistry and Molecular Biology, University of Maryland, Baltimore, MD, March 2000

20.      ÒNuclear-cytoplasm trafficking and oncogenesisÓ. Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, May 2000

21.      ÒNuclear-cytoplasm trafficking and oncogenesisÓ. Department of Pathology, Virginia Commonwealth University, Richmond, VA, September 2000

22.      ÒMolecular profiling of human hepatocellular carcinomaÓ. Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, April 2001

23.      ÒMolecular pathogenesis of liver cancerÓ. The 9th International Congress of Toxicology, Brisbane, Australia, September 2001

24.      ÒNucleocytoplasmic transport, spindle assembly and chromosomal stabilityÓ. The 16th Aspen Cancer Conference, Aspen, CO, July 2001

25.      ÒMolecular profiling of human hepatocellular carcinomaÓ. Multicenter Hemophilia Cohort Study-II, Washington, DC, January 2002

26.      ÒMolecular profiling of human hepatocellular carcinomaÓ. Molecular Genomics 2002: profiling of gene expression, Galveston, TX, 2002

27.      ÒMolecular profiling of human hepatocellular carcinomaÓ. Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, March 2002

28.      ÒMolecular profiling of human hepatocellular carcinomaÓ. Clinical Center, NIH, Bethesda, MD, May 2002

29.      ÒMolecular profiling of human hepatocellular carcinomaÓ. FASEB Summer Research Conference on "Mechanisms of Liver Growth, Differentiation and Molecular Pathogenesis of Hepatic Diseases, Snow Mass, CO, July 2002

30.      ÒMolecular profiling of human hepatocellular carcinomaÓ. International Workshop on Human Hepatocellular Carcinoma, Bethesda, MD, September 2002

31.      ÒMolecular pathogenesis of human hepatocellular carcinomaÓ. Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, October 2002

32.      ÒMolecular pathogenesis of human hepatocellular carcinomaÓ. Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China October 2002

33.      ÒMolecular profiling of human hepatocellular carcinomaÓ. Thomas Jefferson University, Jefferson Center for Biomedical Research, Doylestown, PA, January 2003

34.      ÒMolecular pathogenesis of human hepatocellular carcinomaÓ. Bernie Carter Center for Immunology Research, University of Virginia Health Sciences Center, Charlottesville, VA. March 2003

35.      ÒLesson learned from molecular profiling of human hepatocellular carcinomaÓ. Graduate Class for Topics in Molecular Epidemiology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, May 2003

36.      ÒLesson learned from molecular profiling of human hepatocellular carcinomaÓ. The Thirteenth International Symposium of Hiroshima Cancer Seminar, Hiroshima, Japan, October 2003.

37.      ÒLesson from molecular profiling of human hepatocellular cancerÓ. Symposium on molecular diagnosis of human cancer sponsored by Shanghai Medical Association, Shanghai, China, November 2003.

38.      ÒLesson learned from molecular profiling of human hepatocellular cancerÓ. The GW Cancer Institute, the George Washington University Medical Center, Washington DC, January 2004.

39.      ÒLesson learned from molecular profiling of human hepatocellular carcinomaÓ. Hong Kong-Shanghai International Liver Congress 2004, Hong Kong, China, February 2004.

40.      ÒMetastatic signature of hepatocellular cancerÓ. The 19th Aspen Cancer Conference, Aspen, Colorado, August 2004.

41.      ÒMolecular signature of liver cancer metastasisÓ. The 3rd International Conference on Gastroenterological Carcinogenesis, Sapporo, Japan, August 2004.

42.      ÒMolecular profiling of chronic liver diseases and hepatocellular cancerÓ. The 35th Environmental Mutagen Society Annual Meeting, Pittsburgh, Pennsylvania, October 2004.

43.      ÒMolecular profiling of chronic liver diseases and hepatocellular cancerÓ. Guest speaker, Division of Gastroenterology and Liver Diseases, Mount Sinai School of Medicine; New York, New York, October 2004.

44.      Keystone Symposia Program Committee Meeting (as an ad hoc member), Keystone, Colorado, January 2005.

45.      Frontiers in Oncology Seminar Series: ÒProgress on molecular diagnosis and molecular targets for human hepatocellular carcinomaÓ. Distinguished lecturer, University of Maryland Greenebaum Cancer Center, Baltimore, MD, March 2005.

46.      ÒMolecular signatures of metastatic hepatocellular carcinomaÓ. Invited speaker, The National Cancer Institute Liver Cancer Symposium, Bethesda, MD, April 2005

47.      ÒMetastatic signature of hepatocellular carcinomaÓ in New Concepts in Organ-Site Research. Invited speaker, The 96th Annual Meeting of the American Association for Cancer Research, Anaheim, CA, April 2005

48.      ÒCytokines in human hepatocellular carcinomaÓ. Invited speaker, The NCI inflammation and liver cancer conference, Bethesda, MD, December 2005

49.      ÒHepatocellular Carcinoma: State-of-the-Art on molecular diagnosis and therapeutic opportunityÓ. Speaker and co-organizer, NCI Symposium, Shanghai-Hong Kong International Liver Congress 2006, Shanghai, China, March 2006

50.      ÒRole of liver microenvironment in metastasisÓ. Invited speaker, CNIO Cancer Conference, Madrid, Spain, May 2006

51.      ÒLiver microenvironment and hepatocarcinogenesisÓ. Invited speaker, the 4th International Society of Gastroenterological Carcinogenesis Conference, Hawaii, August 2006

52.      ÒInflammation, cytokines and hepatocellular carcinomaÓ. Invited speaker, The GTCbio 5th annual conference on Cytokines and Inflammation, Breckenridge, CO, January 2007

53.      ÒThe art of liver cancer prognosis: from the view point of biologyÓ in New Concepts in Organ-Site Research. Invited speaker, The 96th Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, April 2007

54.      ÒHepatocellular Carcinoma: A Genomic PerspectiveÓ. Invited speaker, Center for Human Genomics Seminar Series, Wake Forest University School of Medicine, May, 2007

55.      ÒInterrogating the genome in hepatocellular carcinomaÓ. Invited speaker, Cancer Genetics and Epidemiology Program Monthly Seminar Series, the Lombardi Cancer Center at Georgetown University, Washington, DC, June 2007

56.      ÒInterrogating the genome in hepatocellular carcinomaÓ. Invited speaker, National Institute for Occupational Safety and Health Seminar, CDC, Morgantown, WV; August 22, 2007

57.      ÒInflammatory architects of metastatic hepatocellular carcinomaÓ. Invited speaker, Annual symposium of the NCI Center of Excellence in Immunology, Bethesda, MD, October, 2007

58.      ÒDiagnostic and prognostic signatures of liver cancerÓ. Co-organizer and speaker, Keystone Symposia on GI cancer, Beijing, China, October 2007

59.      ÒHepatocellular carcinoma: a genomic perspectiveÓ. Invited speaker, UMMS Immunobiology and Transplantation Biology Research Conference, November, 2007

BIBLIOGRAPHY

 

Articles in Peer-Reviewed Journals

 

1.         Huang, C. C., Han, J. X., Yue, X. F., Shen, Z. M., Wang, X. W., Wu, F. G. and Xu, B.: Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China. Journal of National Cancer Institute 71: 841‑847, 1983.

 

2.         Wang, X. W., Yue, X. F., Han, J. X., Wu, F. G., Shen, Z. M., Xu, B. and Huang, C. C.: Studies on cytotoxicity and induction of sister chromatid exchanges in V79 cells with three antitumor agents. KEXUE TONGBAO 29: 1268‑1271, 1984.

 

3.         Wang, X. W., Yu, W. J., Shen, Z. M., Yang, J. L. and  Xu, B.:  Cytotoxicity of hydroxycamptothecin and four other antineoplastic agents on KB cells. Acta of Pharmacology Sinica 8: 86‑90, 1987.

 

4.         Wang, X. W., Shen, Z. M., Yang, J. L. and  Xu, B.:  Inhibitory effect of hydroxy‑camptothecin on colony formation of KB cells and DNA damage. Acta of Pharmaceutics Sinica 21: 492‑497, 1986.

 

5.         Sugiyama, M., Wang, X. W. and Costa, M.:  Comparison of DNA lesions and cytotoxicity induced by calcium chromate in human, mouse and hamster cell lines. Cancer Res 46: 4547‑4551, 1986.

 

6.         Conway, K., Wang, X. W., Xu, L. and Costa, M.:  Effect of magnesium on nickel‑induced genotoxicity and cell transformation. Carcinogenesis 8: 1115‑1121, 1987

 

7.         Zelikoff, J. T., Li, J. H., Hartwig, A., Wang, X. W., Costa, M. and Rossman, T. G.:  Genetic toxicology of lead compounds. Carcinogenesis 9: 1727‑1732, 1988.

 

8.         Wang, X. W., Imbra, R. J. and Costa, M.:  Characterization of mouse cell lines resistant to nickel (II) ions. Cancer Res 48: 6850‑6854, 1988.

 

9.         Imbra, R. J., Wang, X. W. and Costa, M.:  Characterization of a nickel resistant mouse cell line. Biological Trace Element Research 21: 97‑103, 1989.

 

10.      Wang, X. W. and Costa, M.:  Alteration of nickel binding proteins in nickel resistant cell. Cancer Comm 1(6): 351‑358, 1989.

 

11.      Klein, C. B., Conway, K., Wang, X. W., Bhamra, R. F., Lin, X. H., Cohen, M. D., Lois, A., Barrett, J. C. and Costa, M.:  Senescence of nickel‑transformed cells by a mammalian X chromosome: possible epigenetic control. Science 251: 796‑799, 1991.

 

12.      Wang, X. W. and Costa, M.:  Changes in protein phosphorylation in wild type and nickel‑resistant cells and their involvement in morphological elongation. Biol Metal  4: 201‑206, 1991.

 

13.      Wang, X. W., Lin, X. H., Klein, C. B., Bhamra, R. F., Lee, Y‑W. and Costa, M.:  A conserved region in human and Chinese hamster X chromosomes can induce cellular senescence of nickel‑transformed Chinese hamster cell lines.  Carcinogenesis  13: 555-561, 1992.

 

14.      Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J-R. and Harris, C. C.:  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91: 2230-2234, 1994.

 

15.      Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.-M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H. J., Forrester, K. and Harris, C. C.:  p53 modulation of TFIIH associated nucleotide excision repair activity.  Nature Genetics 10: 188-195, 1995.

 

16.      Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Wang, X. W. and Harris, C. C.:  Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.  Oncogene 10: 2103-2111, 1995.

 

17.      Wang, X. W., Gibson, M., Vermulen, W., Yeh, H., Forrester, K., Sturzbacher, H.-W., Hoeijmakers, J. H. J. and Harris, C. C.:  Abrogation of p53-induced apoptosis by the hepatitis B viral X gene.  Cancer Res 55: 6012-6016, 1995.

 

18.      Forrester, K., Ambs, S., Lupold, S. E., Kapust, R. B., Spillare, E. A., Weinberg, W.C., Felley-Bosco, E., Wang, X. W., Geller, D. A., Billiar, T. R. and Harris, C. C.:  Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild-type p53.  Proc Natl Acad Sci USA 93: 2442-2447, 1996.

 

19.      Wang, X. W., Vermulen, W., Coursen, J. D., Gibson, M. J., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H. J. and Harris, C. C.:  The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.  Genes Dev 10: 1219-1232, 1996.

 

20.      Xu, G. W., Sun, Z. T., Forrester, K., Wang, X. W., Coursen, J. D. and Harris, C.C.:  Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 24: 1264-1268, 1996.

 

21.      Wang, X. W. and Harris, C. C.:  TP53 tumor suppressor gene: clues to molecular carcinogenesis and cancer therapy. Cancer Surveys 28: 169-196, 1996.

 

22.      Adler, V., Pincus, M. R., Minamoto, T., Fuchs, S. Y., Bluth, M. J., Brandt-Rauf, R.W., Friedman, F. K., Robinson, R. C., Chen, J. M., Wang, X. W. Harris, C. C. and Ronai, Z.: Conformation-dependent phosphorylation of p53.  Proc Natl Acad Sci USA 94: 1686-1691, 1997.

 

23.      Buchhop, S., Gibson, M. K., Wang, X. W., Wagner, P., Sturzbecher, H.-W. and Harris, C. C.:  Interaction of p53 with the human Rad51 protein. Nucleic Acid Res 25: 3868-3874, 1997.

 

24.      Wang, X. W. and Harris, C. C.: p53 modulation of cell cycle and apoptosis.  Scanning Microscopy 11: 953-965, 1997.

 

25.      Wang, X. W. and Harris, C. C.:  p53 tumor-suppressor gene: clues to molecular carcinogenesis.  J Cell Physiol 173: 247-255, 1997.

 

26.      Elmore, L. W., Hancock, A. R., Chang, S.-F., Wang, X. W., Chang, S., Callahan, C. P., Geller, D. A., Will, H. and Harris, C. C.:  Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis.  Proc Natl Acad Sci USA 94: 14707-14712, 1997.

 

27.      Parekh, T. V., Wang, X. W., Makri-Werzen, D. M., Greenspan, D. S. and Newman, M. J.: Type V collagen is an epithelial cell cycle inhibitor that is induced by and mimics the inhibitory effects of TGF-β1. Cell Growth & Differ 9: 423-433, 1998.

 

28.      Jia, L., Wang, X. W. and Harris, C. C.:  Hepatitis B virus X protein inhibits nucleotide excision repair.  Int J Cancer 80: 875-879, 1999.

 

29.      Zhan, Q., Antinore, M. J., Wang, X. W., Carrier, F., Smith, M. L., Harris, C. C. and Fornace, A. J. Jr: Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity by the p53-regulated protein Gadd45.  Oncogene 18: 2892-2900, 1999.

 

30.      Zhou, X., Wang, X. W., Xu, L., Hagiwara, K., Nagashima, M. and Harris, C. C.: C‑terminal domain (CTD) of p53 is involved in p53‑mediated apoptosis and transcriptional transactivation. Cancer Res 59: 843-848, 1999.

 

31.      Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C., Ried, T. and  Deng, C. X.:  Centrosome amplification and a defective G2/M checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient mice.  Mol Cell 3: 389-395, 1999.

 

32.      Wang, X. W., Coursen, J. D., Zhan, Q., Fornace, A. J., Jr and Harris, C. C.:  GADD45 induction of a G2-M cell cycle checkpoint.  Proc Natl Acad Sci USA 96: 3706-3711, 1999.

 

33.     Robles, A. I., Wang, X. W. and Harris, C. C.:  Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of p53 interaction with TFIIH in the induction of apoptosis.  Oncogene 18: 4681-4688, 1999.

 

34.     Spillare, E. A., Robles, A. I., Wang, X. W., Shen, J-C., Yu, C-E., Schellenberg, G. D. and Harris, C.C.:  p53-mediated apoptosis is attenuated in Werner Syndrome Cells.  Genes Dev 13: 1355-1360, 1999.

 

35.     Mazur, S. J., Sakaguchi, K., Appella, E., Wang, X. W., Harris, C. C. and Bohr, V. A.: Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. J Mol Biol 292: 241-249, 1999.

 

36.     Wang, X. W.:  Role of p53 and apoptosis in carcinogenesis. Anticancer Res 19: 4759-4771, 1999.

 

37.     Yoo, J. Y., Wang, X. W., Rishi, A. K., Lessor, T., Xia, X. M., Gustafson, T. A. and Hamburger, A. W.:  Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer 82: 683-690, 2000.

 

38.     Yang, Q., Manicone, A., Coursen, J. D., Linke, S. P., Nagashima, M., Forgues, M., and Wang, X. W.  Involvement of a unique acidic motif (DEDDDR) in a GADD45-medicated G2/M Checkpoint.  J Biol Chem 275: 36892-36898, 2000.

 

39.     Liu, J., Akoulitchev, S., Weber, A., Ge, H., Chuikov, S., Libutti, D., Wang, X.W., Conaway, J.W., Harris, C.C., Conaway, R.C., Reinberg, D. and Levens, D. Defective interplay of activators and repressors with TFIIH in Xeroderma Pigmentosum. Cell 104: 353-363, 2001.

 

40.     Huo, T-I, Wang, X.W., Forgues, M., Wu, C-G, Spillare, E. A., Giannini, C., Brechot, C. and Harris, C.C. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 20: 3620-3628, 2001.

 

41.     Brosh, R.M. Jr., Karmakar, P., Sommers, J.A., Yang, Q., Wang, X.W., Spillare, E.A., Harris, C.C. and Bohr, V.A. p53 modulates the exonuclease activity of Werner syndrome protein. J Biol Chem 276: 35093-35102, 2001.

 

42.     Wang, X.W., Tseng, A., Ellis, N. A., Spillare, E. A., Linke, S. P., Robles, A.I., Seker, H., Yang, Q., Hu, P., Beresten, S., Bemmels, N.A., Garfield, S. and Harris, C. C. Functional interaction of p53 and BLM DNA helicase in apoptosis. J Biol Chem 276: 32948-32955, 2001.

 

43.     Nagashima, M., Shiseki, M., Miura, K., Hagiwara, K., Linke, S.P., Pedeux, R., Wang, X.W., Yokota, J., Riabowol, K. and Harris, C.C. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA 98: 9671-9676, 2001.

 

44.     Wu, C-G, Salvay, D.M., Forgues, M., Valerie, K., Farnsworth, J., Markin, R.S. and Wang, X.W. Distinctive gene expression profiles associated with hepatitis B virus X protein. Oncogene 20: 3674-3682, 2001.

 

45.     Forgues, M., Marogi, A., Wu, C., Spillare, E., Yang, Q., Yoshida, M., Wang, X.W. Involvement of Crm1-mediated nuclear export in hepatitis B virus HBx-mediated transactivation.  J Biol Chem 276: 22797-22803, 2001.

 

46.     Wang, X.W. Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis. Mol Biotechnol 18: 169-177, 2001.

 

47.     Wang, X.W., Hussain, S.P., Huo, T-I, Wu, C-G., Forgues, M., Hofseth, L.J., Brechot, C., Harris, C.C. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-182: 43-47, 2002 (The top ten of most downloaded articles within the toxicology category of all articles published in Elsevier journals in 2003).

 

48.     Staib, F., Hussain, S.P., Hofseth, L.J., Wang, X.W. and Harris, C.C.: p53 and liver carcinogenesis. Human Mutation 21, 201-216, 2003.

 

49.     Yang, Q., Zhang, R., Wang, X.W., Spillare, E.A., Linke, S.P., Subramanian, D., Griffith, J.D., Li, J-L, Hickson, I.D., Shen, J.C., Loeb, L.A., Mazur, S.J., Appella, E., Brosh, R.M., Karmakar, P., Bohr, V.A., Harris, C.C. The processing of holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem 277: 31980-31987, 2002.

 

50.     Wu, C-G, Forgues, M., Siddique, S., Farnsworth, J., Kristoffer, V., Wang, X.W.: SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein. FASEB J 16: 1665-7, 2002.

 

51.     Linke, S.P., Sengupta, S., Khabie, N., Jeffries, B.A., Buchhop, S., Miska, S., Henning, W., Pedeux, R., Wang, X.W., Hofseth, L.J., Yang, Q., Garfield, S.H., Sturzbecher, H.-W., and Harris, C.C. (2003). p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 63, 2596-2605, 2003.

 

52.     Kim, J.W. and Wang, X. W.  Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 24, 363-369, 2003.

 

53.     Ye, Q.H., Qin, L.X., Forgues, M., He, P, Kim, J.W., Peng, A.C., Simon, R., Li, Y., Robles, A.I., Chen, Y., Ma, Z.C, Wu, Z.Q, Ye, S.L., Liu, Y.K., Tang, Z.Y. and Wang, X.W. Predicting Hepatitis B Virus-Positive Metastatic Hepatocellular Carcinomas Using Gene Expression Profiling and Supervised Machine Learning. Nat Med 9, 416-423, 2003.

 

54.      Forgues, M., Difilippantonio, M.J., Linke, S.P., Ried, T., Nagashima, K., Feden, J., Valerie, K., Fukasawa, K., Wang, X.W. Involvement of Crm1 in HBx-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 23, 5282-5292, 2003.

 

55.      Ashktorab, H., Ahmed, A., Littleton, G., Wang, X.W., Allen, C.R., Tackey, R., Walters, C., Smoot, D.T. p53 and p14 increase sensitivity of gastric cells to H. pylori-induced apoptosis. Dig Dis Sci. 48, 1284-91, 2003.

 

56.      Yang, Q., Zhang, R., Wang, X.W., Linke, S.P., Sengupta, S., Hickson, I.D., Pedrazzi, G., Perrera, C., Stagljar, I., Littman, S.J., Modrich, P., and Harris, C.C. The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase in homologous DNA recombination. Oncogene 23, 3749-3756, 2004.

 

57.      Budhu, A.S., Zipser, B., Forgues, M., Ye, Q.H., Qin, L.X., Tang, Z.Y., Chen, Y., Simon, R., Sun, Z., Wang, X.W.: The Molecular signature of metastases of human hepatocellular carcinoma. Toxicologic Pathology 32: 730-731, 2004

 

58.      Hofseth LJ, Robles AI, Yang Q, Wang XW, Hussain SP, Harris C. p53: at the crossroads of molecular carcinogenesis and molecular epidemiology. Chest 125, 83S-5S, 2004

 

59.      Kim, J.W., Ye, Q.H., Forgues, M., Chen, Y., Budhu, A., Sime, J., Hofseth, L.J., Kaul, R. and Wang, X.W.: Cancer-associated molecular signatures in the cirrhotic tissue samples of patients with chronic liver disease. Hepatology 39, 518-27, 2004.

 

60.      Budhu, A.S., Zipser, B., Forgues, M., Ye, Q.H., Sun, Z., Wang, X.W.: The Molecular signature of metastases of human hepatocellular carcinoma. Oncology 69 (S2), 2005.

 

61.      Zhang, Y., Wang, X.W., Yu, M.H., Nakanishi, T., Kainate, D., Jelovic, D., Goulbeva, O., Ross, D.D., Brodie, A. and Hamburger, A.W. The ErbB3 binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA 102, 9890-5, 2005.

 

62.      Wang, W., Budhu, A., Forgues, M., and Wang, X.W. Temporal and spatial control of nucleophosmin by the Ran/Crm1 complex in centrosome duplication. Nat Cell Biol 7, 823-30, 2005.

 

63.      Budhu, A.S. and Wang, X.W. Loading and Unloading: Orchestrating Centrosome Duplication and Spindle Assembly by Ran/Crm1. Cell Cycle 4, 1508-12 2005.

 

64.      Spillare, E.A., Wang, X.W. von Kobe, C., Bohr, V.A., Hickson, I.D. and Harris, C.C. Redundancy of DNA helicases in p53-mediated apoptosis. Oncogene 25, 2119-23, 2006.

 

65.      Staib F, Robles AI, Varticovski L, Wang XW, Sirotin N, Zhurkin VB, Hofseth LJ, Hussain SP, Galle PR, and Harris CC: The p53 tumor suppressor network is a key responder to microenvironment components of chronic inflammation stress. Cancer Res.  65, 10255-10264, 2005.

 

66.      Wu, C.G., Budhu, A., Chen, S., Zhou X., Ionescu, N.C., Valerie, K. and Wang, X.W. Effect of Hepatitis C virus Core Protein on the Molecular Profiling of Human B lymphocyte. Mol Med 12, 47-53, 2006.

 

67.    Lambaa, J.K., Chen, X., Lan, L.B., Kim, J.W., Wang, X.W., Relling, M.V. Kazuto, Y., Watkins, P.B, Strom, S., Sun, D., Schuetz, J.D. and Schuetz, E.G. Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. Pharmacogenetics and Genomics 16, 415-427, 2006

 

68.    Budhu, A., Forgues, M., Ye, Q.H., Jia, H.L., He, P., Zanetti, K.A., Kammula, U.S., Chen, Y., Qin, L.X., Tang, Z.Y., and Wang, X.W. Prediction of metastatic potential and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10, 99-111, 2006.

 

69.    Budhu, A and Wang, X.W. Role of cytokines in hepatocellular carcinoma. J. Leukocyte Biology 80, 1197-213, 2006.

 

70.    Lim, M.J. and Wang, X.W. Nucleophosmin and human cancer. Cancer Detection and Prevention 30, 481-90, 2006.

 

71.    Budhu, A and Wang, X.W. The role of nucleophosmin in Ran/Crm1-mediated centrosome duplication.  Center for Cancer Research Frontiers in Science, 5, 2006.

 

72.    Jia, H.L., Ye, Q.H., Qin, L.X., Budhu, A., Forgues, M., Chen, Y., Liu, X.K., Sun, H.C., Wang, L., Tang, Z.Y. and Wang, X.W. Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma Including Those with Normal Serum Alpha-Fetoprotein and Small Tumors. Clin Cancer Res, 13, 1133-9, 2007.

 

73.    Takafuji, V.A., Forgues, M., Unsworth, E., Goldsmith, P., Wang, X.W. A 5-kD osteopontin segment cleaved by matrix metalloproteinase-9 activity is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene, 26, 6361-71, 2007.

 

74.    Hussain, S.P., Schwank, J., Staib, F., Wang, X.W., Harris, C.C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 26, 2166-76, 2007.

 

75.    Chen, X.C., Yu, B., Dong, J.C., Gu, Y.X., Chen, L., Wu, Q.Z., Hou, N.P., Liu, J.X., Xu, J.T., Jin, R.X., Jin, G.Q., Yang, X.D., Cao, Y.W., Tan, J.J., Zhu, B., Shen, J.C., Xu, Z., Varticovski, L. and Wang, X.W. A Phase II Clinical Trial with Cytotropic Heterogeneous Molecular Lipids (CHML¨) for Patients with Hepatic Malignancies. Anticancer Res, 27, 1593-1600, 2007.

 

76.    Budhu, A., Chen, Y., Kim, J.W., Forgues, M., Valerie, K., Harris, C.C. and Wang, X.W. Gene expression profiling of primary human hepatocytes expressing hepatitis C viral proteins. Carcinogenesis, 28, 1552-60, 2007.

 

77.    Seike, M., Yanaihara, N., Bowman, E.D., Zanetti, K.A., Mechanic, L.E., Budhu, A., Kumamoto, K., Yokota, J., Gemma, A., Kudoh, S., Wang, X.W., Harris, C.C. A cytokine gene signature of the lung environment predicts lymph node metastasis and prognosis of lung adenocarcinoma. Journal of National Cancer Institute, 99, 1257-69, 2007.

 

78.    Roessler, S, Budhu, A., Wang, X.W. The future of molecular profiling of human hepatocellular carcinoma. Future Oncol, 3, 429-439, 2007.

 

79.    Yoshikawa, H., Matsubara, K., Zhou, X., Okamura, S., Kubo, T., Murase, Y., Shikauchi, Y., Esteller, M., Herman, J.G., Wang, X.W., Harris, C.C. WNT10B functional dualism: b-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. Mol Biol Cell, 18, 4292-303, 2007.

 

80.    Yamashita, T., Forgues, Budhu, A., Wang, X.W. Activation of hepatic stem cell marker EpCAM by Wnt-b-catenin signaling in hepatocellular carcinoma. Cancer Res, 67, 10831-9, 2007.

 

81.    Budhu, A., Jia, H.L., Forgues, M., Liu, C.G., Goldstein, D., Lam, A., Zanetti, K.A., Ye, Q.H., Qin, L.X., Croce, C.M., Tang, Z.Y., Wang, X.W. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 47, 000-000, 2008

 

82.    Yamashita, T., Forgues, M., Kim, J.W., Wang, W., Ye, Q.H., Jia, H.L., Budhu, A., Takafuji, V.A., Zanetti, K., Chen, Y., Qin, L.X., Tang, Z.Y., Wang, X.W. EpCAM and a-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res, in press.

 

Chapters in Books

 

1.         Xu, B., Wang, X. W., Han, J. X. and Huang, C. C.:  Cytotoxicity and induction of sister chromatid exchanges (SCE) in vitro by several antitumor drugs.  In: Mutation, Cancer and Malformation, Chu, E. H. Y. and Generoso, W. M. eds., Plenum, NY,  pp. 819, 1984.

 

2.         Costa, M., Conway, K., Imbra, R. and Wang, X. W.:  The involvement of heterochromatin damage in nickel‑induced transformation and resistance. In: Nickel and Human Health: Current Perspectives, Nieboer, E. and Antio, A., eds., John Wiley and Sons, Inc., NY, Advances in Environmental Science and Technology, 1990.

 

3.         Costa, M., Christie, N. T., Cantoni, O., Zelikoff, J. T., Wang, X. W. and Rossman, T. G.: DNA damage by mercury compounds, an overview. Advances in Mercury Toxicology, Suzuk, ed., Plenum, NY, pp. 255‑273, 1991.

 

4.         Jia, L., Wang, X. W., Sun, Z. and Harris, C. C.:  Interactive effects of p53 tumor suppressor gene and hepatitis B virus in hepatocellular carcinogenesis. In: Molecular Pathology of Gastroenterological Cancer: application to clinical practice.  Tahara, E. ed., Springer-Verlag, Tokyo, pp. 209-218, 1997.

 

5.         Wang, X. W., Greenblatt, M. S. and Harris, C. C.:  Molecular genetics of lung cancer.  In: Clinical and Biological Basis of Lung Cancer Prevention. Martinet, Y., Hirsch, F.R., Martinet, N., Vignaud, J.-M, Mulshine, J.L., eds, Birkhauser Verlag, Basel, pp. 117-127, 1998.

 

6.         Hussain, S.P., Wang, X.W., Shields, P.G. and Harris, C.C.: Gene-environment interactions in human cancer risk. In: Chemicals in the 21st century, chemicals for sustainable development. Proceedings of the Fourth Princess Chulabhorn International Science Congress. Bangkok, Trinity Publ. Co., pp. 39-49, 1999.

 

7.         Wang, X. W.: Abrogation of p53-induced apoptosis by the hepatitis B virus X gene.  In: Methods in Molecular Medicine, vol. 45: Hepatocellular Carcinoma Methods and Protocols. Habib, N. edt. Humana Press Inc. Totowa, NJ, 57-70, 2000.

 

8.         Hofseth, L. J., Hussain, S. P., Wang, X. W. and Harris, C. C. Hepatocellular Cancers: Molecular biology and genetics. In: Principles and Practices of Gastrointestinal Oncology. Kelsen, D. P., Daly, J., Levin, B., Tepper, J., Kern, S. Eds. Philadelphia, Lippincott Williams & Wilkins, pp. 539-558, 2002.

 

9.         Elmore, L.W., Wang, X.W., Harris, C.C. Hepatocellular Carcinoma. In: Encyclopedia of the Human Genome. Cooper, D.N. Ed. Nature Publishing Group. pp. 216-220, 2003.

 

10.      Budhu, A. and Wang, X.W. The Role of Hepatitis Viruses in Liver Oncogenesis. In: Recent Research Developments in Molecular Biology. S.G. Pandalai, Ed. Research Signpost, 1: 97-118, 2003.

 

11.      Budhu, A. and Wang, X.W. Human hepatocellular carcinoma: New insights from gene expression profiling. In: Progress in Liver Cancer Research. F. Columbus, Ed. Nova Science Publishers, Inc., 2006.

 

12.      Budhu, A and Wang, X.W. The functional relevance of HBx subcellular localization and nuclear shuttling. In: The pleiotropic functions of the viral protein HBx in Hepatitis B virus infection and the development of liver cancer. J. Kobarg, Ed. Research Signpost, 2007.

 

13.      Hussain, S.P., Wang, X.W., Harris, C.C. Inflammation and human cancer. In: Pathogenesis and clinical practice in gastroenterology. Ed. Lancaster Publishing Services, United Kingdom, 000-000, 2008.